Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A.
Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A.
复制标题
GR1501 的临床前开发,GR1501 是一种中和 IL-17A 的人单克隆抗体。
DOI:
10.1016/j.bbrc.2019.07.078
复制
发表时间:
2019-09
期刊:
影响因子:
--
通讯作者:
Xu Qiang
中科院分区:
文献类型:
--
作者:
Shan Yunlong;Shi Ke;Qian Xuelong;Chang Zhiyuan;Yang Jiaqian;Gao Yuan;Jin Wei;Luo Qiong;Xu Qiang
Interleukin-17A (IL-17A) is a soluble pro-inflammatory cytokine, which is mainly secreted by Th17 cells. In humans, IL-17A mRNA and protein levels are increased in several autoimmune diseases, including psoriasis and rheumatoid arthritis. This study describes the preclinicalin vitroandin vivocharacterization of GR1501, a human IL-17A-neutralizing IgG4 monoclonal antibody. GR1501 binds human, rhesus and cynomolgus IL-17A with high affinity but does not bind to mouse IL-17A or other IL-17 family members. GR1501 effectively blocks the interaction between IL-17A and its receptor IL-17RA, thereby inhibiting IL-17A-induced CXCL1 and IL-6 release in cells and mice. In mouse air pouch model, GR1501 effectively inhibits IL-17A induced leukocytes infiltration into the air pouch. GR1501 also reduces joint swelling and inflammation in mouse arthritis model. These data suggest that GR1501 is a potent and selective IL-17A-neutralizing monoclonal antibody and will support the clinical investigation of this monoclonal antibody in psoriasis and rheumatoid arthritis.
登录
查看更多内容
影响因子:
4.8
作者:
Chang SH;Dong C
通讯作者:
Dong C
影响因子:
32.4
作者:
Stark, MA;Huo, YQ;Ley, K
通讯作者:
Ley, K
影响因子:
158.5
作者:
Langley, Richard G.;Elewski, Boni E.;Papavassilis, Charis
通讯作者:
Papavassilis, Charis
DOI:
10.1016/j.disamonth.2018.06.001
发表时间:
2019-03
期刊:
Disease-a-month : DM
影响因子:
--
作者:
Eric D Schadler;B. Ortel;S. Mehlis
通讯作者:
Eric D Schadler;B. Ortel;S. Mehlis
DOI:
10.4049/jimmunol.1800013
发表时间:
2018-09-15
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
Hawkes JE;Yan BY;Chan TC;Krueger JG
通讯作者:
Krueger JG